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Abstract
Background: In 2009, xenotropic murine leukemia virus-related virus (XMRV) was reported in 67% of patients with
chronic fatigue syndrome (CFS) compared to 4% of controls. Since then numerous reports failed to detect XMRV in
other cohorts of CFS patients, and some studies suggested that XMRV sequences in human samples might be due
to contamination of these samples with mouse DNA.
Results: We determined the prevalence of XMRV in patients with CFS from similar areas in the United States as
the original 2009 study, along with patients with chronic inflammatory disorders and healthy persons. Using
quantitative PCR, we initially detected very low level signals for XMRV DNA in 15% of patients with CFS; however,
the frequency of PCR positivity was no different between patients with CFS and controls. Repeated attempts to
isolate PCR products from these reactions were unsuccessful. These findings were supported by our observations
that PHA and IL-2 stimulation of peripheral blood mononuclear cells from patients with apparently low levels of
XMRV, which induced virus replication in the 2009 report, resulted in the disappearance of the signal for XMRV
DNA in the cells. Immunoprecipitation of XMRV-infected cell lysates using serum from patients from whom we
initially detected low levels of XMRV DNA followed by immunoblotting with antibodies to XMRV gp70 protein
failed to detect antibody in the patients, although one control had a weak level of reactivity. Diverse murine
leukemia virus (MLV) sequences were obtained by nested PCR with a similar frequency in CFS patients and
controls. Finally, we did not detect XMRV sequences in patients with several chronic inflammatory disorders
including rheumatoid arthritis, Bechet’s disease, and systemic lupus erythematosus.
Conclusions: We found no definitive evidence for XMRV DNA sequences or antibody in our cohort of CFS
patients, which like the original 2009 study, included patients from diverse regions of the United States. In addition,
XMRV was not detected in a cohort of patients with chronic inflammatory disorders.
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Background
Chronic fatigue syndrome (CFS) is characterized by
debilitating, unexplained, persistent or relapsing severe
fatigue of new onset that is not relieved by rest or
reduction of activities. In addition, criteria for CFS
require that patients concurrently have four or more of
the following symptoms for ≥6 months (a) impaired
memory or concentration, (b) sore throat, (c) tender
cervical or axillary lymph nodes, (d), muscle pain, (e)
multi-joint pain without redness or swelling, (f) head-
ache, (g) unrefreshing sleep, or (h) post-exertional
malaise. While a large number of infectious agents have
been postulated to cause CFS, further studies have not
confirmed these findings. In 2009, Lombardi et al. [1]
first reported the presence of xenotropic murine leuke-
mia virus-related virus (XMRV) in the blood of 67% of
patients with CFS compared with 3.7% of control sub-
jects. In a recent study, Lo et al. [2] reported the
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presence of murine leukemia virus (MLV)-related virus
gene sequences in 86.5% of CFS patients and 6.8% of
controls. The sequences amplified by nested PCR from
these patients were distinct from XMRV reported by
Lombardi et al. [1]. Recently, a number of other studies
have failed to confirm this observation [3-10]. Recent
studies have suggested that amplification of XMRV
DNA in human samples is due to contamination of
these samples with mouse DNA [11-15].
In view of the controversies linking CFS to MLVs
among different laboratories, we tested our well charac-
terized cohort of chronic fatigue syndrome patients that
fulfilled the CDC case definition [16] for both XMRV
and MLV-related viruses. We failed to find definitive
evidence for XMRV DNA sequences or antibody in our
cohort of CFS patients, which were from diverse areas
of the United States, similar to the cohort reported in
original 2009 study [1,17]. We did, however, detect a
diverse set of MLV-related virus gene sequences at a
similar frequency in CFS patients as in healthy
individuals.
Results
A very weak signal is detected for XMRV in PBMCs from
some patients with CFS, but the frequency of PCR
positivity is not significantly different from controls
In the first set of experiments, we determined the fre-
quency and level of XMRV DNA in blood obtained
from cohort 1 which included patients with CFS (21-61
years), idiopathic chronic fatigue, other viral diseases,
and healthy blood bank donor controls obtained from
1993-2007 (Table 1). As reported previously for patients
with CFS [7-9], most of the patients and controls in the
cohort were Caucasian women ages 40-45. Most
patients and controls were from the Midwest or South-
ern United States; other patients were from the North-
eastern and Western United States.
Real-time qPCR was performed using primers for a
portion of the XMRV integrase gene [18] by a scientist
who was blinded to the identity of the samples. The
PCR assay could reliably detect 5 copies of XMRV DNA
per reaction in the presence of 250 ng of cellular geno-
mic DNA (or 20 copies of XMRV DNA/ug cellular
DNA). Positive samples were defined as those having
detectable DNA in the majority of replicates; at least 3
replicates were performed on each sample. Nine of 61
(15%) samples from patients with CFS were positive for
XMRV DNA in the real-time qPCR assay. The mean
DNA copy number of the positive samples was 21
copies per ug of cellular DNA, with a range of 9.9-37
copies per microgram DNA. There were no significant
differences in the age, gender, or mean years of illness
in XMRV-positive vs. XMRV-negative persons (Table 1).
Patients with low levels of XMRV DNA were more
likely to be from the Midwest and less likely to be from
the Northeast. In contrast, none of the 18 subjects with
idiopathic chronic fatigue, non-CFS viral disease, or
healthy blood bank donors in the cohort was positive
for XMRV. The difference between the PCR positivity
for XMRV in patients with CFS versus patient controls
or healthy blood donors in cohort 1 was not significant
(p = 0.593). Therefore, the very weak signal (less than
twice the lower limit of reliable detection) for XMRV in
the minority of patients with CFS was not conclusively
associated with this disease.
PCR was performed on patients with CFS that were
positive for XMRV DNA using primers specific for
mouse GAPDH or IAP sequences. All of the samples
were negative for mouse GAPDH or IAP DNA; in con-
trast genomic DNA from mouse cells yielded the pre-
dicted size (140 bp for GAPDH and 300 bp for IAP
DNA) band in the assay (data not shown).
We then measured the level of XMRV DNA in the
blood from cohort 2 which included 50 healthy persons
and 97 patients with chronic inflammatory diseases
including 30 with rheumatoid arthritis, 20 with Behcet’s
disease, 10 with systemic lupus erythematosus, and 9
with cryopyrin-associated periodic syndromes (Table 2).
All 97 samples were negative for XMRV DNA. To con-
firm that the genomic DNAs used did not contain any
inhibitor that could account for lack of amplification,
the RNAse P sequences were amplified using an RNAse
P qPCR kit; all 226 samples were positive for RNAse P.
We then tested DNA from all 226 samples in a real-
time qPCR assay for a portion of the XMRV envelope
gene [3]. This PCR assay could not detect fewer than 15
copies of XMRV per 250 ng of genomic DNA; therefore,
it was less sensitive than the XMRV integrase PCR. All
226 DNAs were XMRV-negative using the XMRV envel-
ope assay. These results are similar to prior results in
which XMRV sequences could not be detected in sam-
ples from a CFS cohort from the United Kingdom [3].
XMRV cannot be detected in PBMCs from patients with
CFS by activation of the cells
These data prompted us to carry out further experi-
ments on a subset of qPCR-positive and negative sam-
ples by looking for the amplification of XMRV proviral
DNA after activation of patient PBMC by PHA and
further stimulation with IL-2. No amplification was
observed using the integrase based qPCR assay, includ-
ing those that scored positive in the initial assay. In
addition, repeated attempts to isolate and clone PCR-
amplified DNA from a subset of the qPCR-positive sam-
ples were unsuccessful. This suggests that the samples
that were weakly positive initially in the CFS patients
may have been due to non-specific amplification of cel-
lular DNA or a falsely positive signal.
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PBMCs from patients with CFS are not more likely to
have a signal for MLV-related viruses than controls
Recently MLV-related virus DNA was detected in patients
with CFS using nested PCR [2]. Initially we used Taq poly-
merase (Invitrogen) that does not contain the mouse
monoclonal antibody present in Platinum Taq. However,
no signal was observed in the patient or control samples.
Therefore, we used Platinum Taq polymerase (the Taq
polymerase used by Lo et al. [2], but the no template con-
trols also amplified a DNA product. However, a new lot of
Table 1 Characteristics of Subjects in Cohort 1 Evaluated for XMRV.
Chronic fatigue syndrome Idiopathic chronic fatigue Health blood donors Non-CFS virus disease1
No. persons 61 6 9 3
XMRV+/- 9/52 0/6 0/9 0/3
Age, yrs XMRV+/-
Mean 44/43 41 35 41
Median 45/43 42 31 41
Range 30-54/21-61 28-61 16-54 20-56
White (%) 100/94 100 100 67
Women (%) 100/75 83 88 67
Mean yrs. of illness 5/6 5 NA NA
Residential geographic zone2 (%)
Midwest 56/36 67 50 33
Northeast 0/13 0 0 0
South 22/36 33 50 67
West 22/15 0 0 0
CFS. chronic fatigue syndrome; NA, not applicable
1Non-CFS viral diseases: one case each of chronic active hepatitis B virus infection, echovirus 6 associated meningoencephalitis; and acute Epstein-Barr virus
infection, early convalescent stage.
2Geographic zones based on Census Regions and Divisions of the United States, U.S. Department of Commerce Economics and Statistics Administration, U.S.
Census Bureau
Table 2 Results of PCR for patients with chronic fatigue syndrome and controls.
Patient category No.
Subjects




Nested PCR Pos. for
MLV-RV
Nested PCR Pos. for
XMRV
Cohort 1
CFS 61 9 0 61 0
Idiopathic chronic fatigue 6 0 0 6 0
Non-CFS virus disease* 3 0 0 3 0
Healthy donors 9 0 0 9 1
Cohort 2
Rheumatoid arthritis 30 0 0 10** ND
Behcet’s disease 20 0 0 ND ND
Systemic lupus erythematosus 10 0 0 ND ND
Cryopyrin-associated periodic
syndromes
9 0 0 ND ND
Dermatomyositis 9 0 0 ND ND
Polymyositis 7 0 0 ND ND
Scleroderma 5 0 0 ND ND
Inclusion body myositis 4 0 0 ND ND
Other inflammatory diseases*** 3 0 0 ND ND
Healthy donors 50 0 0 ND ND
*One patient each with chronic active hepatitis B virus infection; echovirus 6-associated meningoencephalitis, and acute Epstein-Barr virus infection, early
convalescent stage
**Only 10 out of a total 30 samples from patients with rheumatoid arthritis were tested in the nested PCR assay
***Other inflammatory diseases: interstitial lung disease, monoclonal gammapathy of undetermined significance, undifferentiated connective tissue disease
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Platinum Taq polymerase was selected which did not
amplify a DNA product in the no template controls.
When this Taq polymerase was used with genomic DNA
template in a nested PCR assay, a 400 bp DNA was readily
amplified from both CFS patients and non-CFS subjects (9
healthy blood donors, 10 patients with rheumatoid arthri-
tis, and 9 other patients). The PCR amplification products
from 14 CFS patients and 8 healthy donors were
sequenced and aligned to sequences in Genbank using a
BLAST search. We identified at least 5 distinctive gag
sequences homologous to endogenous MLVs of the poly-
tropic (Pmv), modified polytropic (Mpmv), or xenotropic
(Xmv) subgroups (Table 3). The sequence from one con-
trol (healthy donor 2) is an MLV-like gag containing a
region highly homologous to Mpmv MLV followed by
sequence with lower homology to known MLVs. Most of
these PCR products were also highly related to MLV-
related sequences that were previously identified in sam-
ples from patients with CFS or prostate cancer [2,19,20].
In addition, a portion of human chromosome 1 was ampli-
fied from two CFS patients and one control sample. While
the numbers of samples analyzed were small, MLV-related
virus sequences were detected in both patients with CFS
and in healthy controls indicating that the amplification of
viral DNA was not specific for CFS. No PCR product was
obtained in the absence of a template or using African
green monkey (Vero) cells or telomerase-transformed rhe-
sus fibroblasts (Telo-RF cells) grown in cell culture.
Patients with CFS and a weak signal for XMRV do not
have detectable antibody to XMRV
Since Lombardi et al. [1] detected antibody to XMRV in
many of their patients with CFS, we also looked for
antibody in our patients. Immunoprecipitation of
XMRV antigens from mock-infected or XMRV-infected
ferret cells using serum from CFS patients and non-CFS
controls, followed by immunoblotting with a polyclonal
goat antibody to XMRV gp70 did not reveal the pre-
sence of antibodies to XMRV gp70 antigen (Figure 1). A
positive control, in which an XMRV gp70-reactive rat
monoclonal antibody 83A25 [21] was used to immuno-
precipitate gp70, readily detected gp70 from XMRV-
infected ferret cells (Figure 1A, B last lanes). A faint
band co-migrating with gp70 was observed in the serum
from one subject without CFS using either XMRV-
infected 293T or ferret cells. The origin of this faint
band was not further investigated. Similar results, show-
ing lack of detectable antibody to XMRV, were also
observed in virus-infected 293T cells (data not shown).
Discussion
We initially detected very weak signals for XMRV in
15% of patients with CFS with a set of XMRV primers
using real-time PCR, but failed to detect XMRV in
patients with idiopathic chronic fatigue, chronic inflam-
matory disorders, other viral infections, or healthy con-
trols. The difference in frequency of a weak PCR
positive signal for XMRV for patients with CFS versus
controls was not significant, thus, these results did not
indicate a clear relationship between XMRV and CFS.
Our repeated failure to isolate and clone XMRV
sequences by PCR from the samples that were low posi-
tive in the real-time PCR assay, suggests that the low
positive signals were false-positive artifacts, rather than
contamination with mouse DNA. Tuke et al. [22]
reported that Invitrogen Platinum Taq PCR Master Mix
Table 3 Comparison of sequences amplified from healthy blood donor and CFS patient PBMC DNAs with sequences of
endogenous MLVs and other patient derived sequences.
Source Length
(bp)
Related mouse sequence: Genbank
number/ID




740 1-357 CU407131 Mouse chromosome 11 Mpmv 97% (346/356) JF288884 (97%) XMRV
HM630559 (97%) MLV-related virus
411-534 AC161435 Mouse chromosome
8
Pmv 74% (80/108) HM630559 (80%) MLV-related virus
Healthy
Donor#4
472 AL356390 (99%) Human chromosome 1
CFS#1 338 CU407131
Mouse chromosome 11
Mpmv 96% (323/338) JF288884 (96%) XMRV
HM630559 (95%) MLV-related virus
CFS#2 437 AL356390 (99%) human chromosome 1
CFS#4 359 FJ544577 Mouse endogenous polytropic
provirus clone 15







CFS#5 472 AL356390 (99%) Human chromosome 1
CFS#6 358 CU407131 Mouse chromosome 11 Mpmv 99% (284/288) JF288884 (99%) XMRV
HM990971(99%)Polytropic endogenous MLV
Abbreviations: CFS, chronic fatigue syndrome; Pmv, endogenous polytropic MLV; Mpmv, endogenous modified polytropic MLV; Xmv, endogenous xenotropic
MLV; M/pmv, endogenous MLV of uncertain subtype
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was contaminated with mouse DNA sequences; how-
ever, they did not detect murine sequences in Applied
Biosystems Taq PCR Master Mix. Since we also used
Applied Biosystems Taq PCR master mix for amplica-
tion of DNA by real-time PCR, this further supports the
likelihood of a false positive signal as an artifact, rather
than contamination with XMRV. We were also unable
to detect XMRV in patients with CFS using a different
set of XMRV primers or in PBMCs activated by PHA
and further stimulated with IL-2 to amplify XMRV
DNA. These latter results are in contrast to those of
Lombardi et al. who found that activation of PBMCs
from patients with CFS with PHA induced expression of
virus proteins and infectious viral particles [1], which
would be expected to amplify XMRV DNA.
Since the original report of Lombardi et al. [1] in
which XMRV DNA was detected in 67% of CFS patients
and 3.7% of controls, there are numerous reports from
the United Kingdom [3,4], the Netherlands [5], China
[6], Japan [12,23], and the United States [7-10,19,24]
that did not detect XMRV DNA in patients with CFS.
Reasons postulated for the difference in results include
geography of the patients, contamination of samples or
reagents with mouse DNA, sequence variation in
XMRV, and definitions of CFS.
The blood samples we evaluated were collected from
the NIH cohort of CFS patients during 1993-1995 and
patients were predominantly from Midwestern and
Southern United States, but also included patients from
Western and Northeastern United States. Lombardi et
al. studied patients from the 2006 to 2008, including
some patients identified during an outbreak of CFS in
1984-1988, and their patients came from at least 11
states in various regions of the country [1,17]. Like our
cohort, their patients were from diverse areas of the
United States. Prior reports generally have studied more
recent patients and most of the patients have been from
more restricted locations in the United States or differ-
ent geographic areas than those of the original report.
Our study more closely resembles that of Satterfield et
al. [24] who studied patients from multiple states of the
continental United States, whereas other studies have
reported patients from a single geographic area of the
United States [8-11], two states [7], or other countries
[3-6,23,25].
Using the nested PCR assay reported by Lo et al. [2],
we detected MLV-related viral DNA in all human sam-
ples tested, regardless of whether they were from
patients with CFS, inflammatory diseases, or normal
controls. Sequence analysis showed that sequences in
both CFS and healthy controls aligned with MLV
sequences found in mice and reported in patients with
CFS or prostate cancer [2,19,20]. In contrast, we did not
detect MLV-related virus in monkey cell lines. While
the nested PCR findings suggest that the human samples
were contaminated with mouse DNA, specific testing for
mouse genomic DNA (testing for both mouse GAPDH
and multi-copy mouse IAP transposons) was negative.
In addition, nested PCR of monkey cell DNA did not
amplify MLV sequences. Thus, the MLV sequences
might be due to contamination during DNA isolation
(from the AllPrep DNA/RNA isolation kit), from Plati-
num Taq (as reported by Tuke et al. [22], or due to
very low levels of MLV related sequences in human
DNA. Using other procedures for isolating DNA and
PCR, Satterfield et al. [24] did not detect MLV in CFS
patients from 17 states in the United States.
Our serologic analysis by immunoprecipitation of gp70
from XMRV-infected 293T or ferret cells using CFS
patient sera and sera from non-CFS control patients did
not detect XMRV gp70 specific antibodies in patients
with CFS. Our results are consistent with those of Erl-
wein et al. [25], Satterfield et al. [24], Knox et al. [9] and
Shin et al. [10] who were unable to detect antibody to
XMRV in patients with CFS.
Since this work was performed, Paprotka et al [15]
and Knox et al [9] have shown that XMRV originated
sometime between 1993 and 1996 from recombination
between two endogenous MLVs during tumor passaging
in mice, and that XMRV could not be detected in 43
patients who had previously been reported XMRV posi-
tive. Our findings, indicating no definitive evidence link-
ing XMRV with CFS both by PCR and by antibody
testing, support those of others that XMRV is not a
Figure 1 Absence of antibody to XMRV gp70 in serum from
patients with CFS. XMRV gp70 protein was immunoprecipitated
from XMRV-uninfected (Un) or XMRV-infected (XMRV) ferret cells
using serum from subjects with (CFS) or without (Cont) CFS or with
a rat monoclonal antibody to gp70. Immune complexes were
separated on 4-20% SDS gels transferred to nitrocellulose
membranes and immunoblotted with goat polyclonal antibody to
XMRV gp70. (A) Sera from CFS patients 13 and 48, and control
subject 22. (B) Sera from CFS patients 59 and 62 and control subject
87. The numbers between the blots are sizes of protein markers in
kilodaltons.
Ali et al. Virology Journal 2011, 8:450
http://www.virologyj.com/content/8/1/450
Page 5 of 8
cause of CFS. Thus, the search must continue for other
etiologies for CFS.
Conclusions
We did not find evidence linking XMRV to CFS by PCR
of PBMCs or by immunoblotting of patient serum.
Furthermore we did not find XMRV sequences in
patients with connective tissue disorders including rheu-
matoid arthritis, Bechet’s disease, and systemic lupus
erythematosus.
Methods
Patients, controls, and DNA isolation
Subjects in cohort 1 with CFS, idiopathic chronic fati-
gue, non-CFS viral disease, and healthy blood donors
were obtained from protocols approved by the Institu-
tional Review Board (IRB) of the National Institute of
Allergy and Infectious Diseases (NIAID). All patients
signed written consents and blood had been obtained
during 1993-1995. CFS was defined using Centers for
Disease Control and Prevention criteria [16]. Idiopathic
chronic fatigue was defined as clinically evaluated, unex-
plained chronic fatigue that failed to meet criteria for
the chronic fatigue syndrome [16]. Healthy donors had
signed consents on an NIAID approved protocol.
Since CFS has been associated with chronic immune
activation, we tested a second group of patients, Cohort
2, which included patients with inflammatory diseases
who had signed consents as part of protocols approved
by the joint National Institute of Diabetes, Digestive and
Kidney Diseases/National Institute of Arthritis and Mus-
culoskeletal and Skin Diseases IRB.
Genomic DNA was extracted from 5-10 × 106 periph-
eral blood mononuclear cells (PBMCs) in patients from
cohort 1 that had been cryopreserved in liquid nitrogen
using an AllPrep DNA/RNA isolation kit (Qiagen,
USA). DNA from PBMCs in patients from cohort 2 was
extracted using various procedures.
PHA-induction and IL-2 stimulation of PBMCs
PBMCs from a subset of cohort 1 were activated by 0.5
ug/ml of PHA-L (Roche Diagnostics), and after 72
hours, cells were cultured with 20 U/ml of recombinant
IL-2 (Biological Resource Branch, NCI) and subcultured
every 3-5 days as described earlier [1]. Genomic DNA
was prepared on day 8 from IL-2-stimulated cells using
an AllPrep DNA/RNA isolation kit as described above.
Real-time quantitative PCR of XMRV DNA
A 121 bp region from the XMRV integrase gene was
amplified by real-time quantitative PCR (qPCR) using
primers 4552F and 4673R and a 5’FAM and 3’TAMRA
labeled probe 4572 as described previously [18]. A sec-
ond real-time qPCR assay for a 71 bp fragment from
the XMRV envelope gene used primers 6173 env F,
6173 env R, and 5’-FAM and 3’-TAMRA labeled 6173
envelope probe as described previously [3].
Reaction mixtures for qPCR contained 1X TaqMan
Universal PCR Master Mix (Applied Biosystems), 1 uM
each of primer, 250 nM of probe and 250 ng of genomic
DNA in a total volume of 25 ul. All PCR reactions were
performed with duplicate samples. Reactions were per-
formed using an ABI 7500 real-Time PCR System
(Applied Biosystems) with the following conditions: 50°
C for 2 min, 95°C for 10 min, 40 cycles at 95°C for 20
sec and 60°C for 1 min. A standard curve consisting of
10-fold serial dilutions (5-50,000 copies) of XMRV pro-
viral DNA VP62 [26; a gift from F. Ruscetti, NCI] spiked
with 250 ng of denatured salmon sperm DNA was
amplified using identical conditions to quantify the pre-
sence of XMRV DNA in the human samples. The assay
can reliably detect 20 copies of XMRV DNA/ug of cellu-
lar DNA. To ensure that no inhibitor was present, the
single copy RNAse P gene was amplified from each 250
ng DNA sample using a TaqMan RNAse P Detection
Reagent kit (Applied Biosystems).
PCR amplification for XMRV and MLV-related virus DNA
Nested PCR of MLV-related virus and XMRV gag
sequences was performed as described by Lo et al. [2].
XMRV DNA was amplified for 40 cycles using primers
419F and 1154R with 50 ng of genomic DNA and 1 U
of Platinum Taq polymerase (Invitrogen) followed by 45
cycles in the 2nd round using either primers GAG-1F
and GAG-1R for XMRV DNA, or primers N116 and
N117 for MLV-related virus [2]. Multiple controls with-
out template were run in each PCR experiment.
PCR amplification of mouse DNA
The presence of mouse DNA was tested by PCR for
mouse GAPDH which is present at 2 copies/mouse gen-
ome as described earlier [26]. Low level contamination
of mouse DNA was tested by amplification of intracis-
ternal A particle (IAP) transposons which are present at
~1000 copies/mouse genome as described previously
[11]. Serial dilutions of mouse DNA were used as posi-
tive controls, and PCR products were analyzed by elec-
trophoresis on agarose gels.
Immunoprecipitation and immunoblotting for XMRV
gp70 protein
The presence of antibodies to XMRV in human serum
samples was tested by immunoprecipitating XMRV anti-
gens from XMRV-infected or mock infected 293T or
ferret cell extracts. Ferret cells were found to yield a
higher level of infection than human cell lines (e.g.
HeLa, 293T cells). 293T cells were obtained from the
American Type Culture Collection (Manassas, VA) and
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MA-139 ferret cells [27] were a gift from Janet Hartley,
NIAID, Bethesda, MD. Briefly, about 40 ul of cell
extracts were mixed with 280 ul of 1× RIPA buffer (10
mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA,
1.0% NP-40, 0.5% deoxycholate and 0.1%SDS). Human
serum (20 ul) or cell culture filtrate containing rat
monoclonal antibody 83A25 [19] to XMRV gp70 (20 ul)
was added. The mixture was incubated on ice for 1 h.
Then 40 ul of a 50% suspension of protein-G-Sepharose
(Sigma-Aldrich) was added and the antigen-antibody
reaction was allowed to proceed for 12-16 h at 4°C in a
rotator. Immune complexes were purified by washing
the beads 3-4 times with 1× RIPA buffer and boiled for
3 min in 1× SDS-PAGE loading buffer (Quality Biologi-
cals). Proteins were separated on 4-20% Tris-glycine
SDS-PAGE gels (Invitrogen), transferred to nitrocellu-
lose membranes, and incubated with a goat polyclonal
antibody to XMRV gp70 (produced by Viromed Biosaf-
ety Laboratories, Camden NJ) at a dilution of 1:3000.
After washing, the membrane was incubated with HRP-
conjugated donkey anti-goat antibody (Santa Cruz
Biotechnology).
Statistics
Fisher’s exact test was used to test the significance
between groups.
List of abbreviations
XMRV: xenotropic murine leukemia virus-related virus; CFS: chronic fatigue
syndrome: MLV: murine leukemia virus; IRB: institutional review board; NIAID:
National Institute of Allergy and Infectious Diseases; PBMCs: peripheral blood
mononuclear cells; IAP; intracisternal A particle; Pmv, polytropic MLV; Mpmv,
modified polytropic MLV; Xmv, xenotropic MLV.
Acknowledgements
This work was supported by the Intramural Research Programs of the
National Institute of Allergy and Infectious Diseases, the National Institute of
Arthritis and Musculoskeletal and Skin Diseases, and the National Institute of
Environmental Health Sciences. We thank Francis Ruscetti for XMRV VP62
plasmid and Jing Qin for performing statistics and Terrance O’Hanlon for
technical assistance.
Author details
1Medical Virology Section, Laboratory of Infectious Diseases, National
Institute of Allergy and Infectious Diseases, National Institutes of Health,
Bethesda, Maryland, USA. 2Viral Biology Section, Laboratory of Molecular
Microbiology, National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Bethesda, Maryland, USA. 3Translational
Autoinflammatory Disease Section, National Institute of Arthritis and
Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda,
Maryland, USA. 4Environmental Autoimmunity Group, National Institute of
Environmental Health Sciences, National Institutes of Health, Bethesda,
Maryland, USA. 5Current Address: Clinical Research Program, Division of
Allergy, Immunology and Transplantation, National Institute of Allergy and
Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Authors’ contributions
All authors read and approved the final manuscript. MAA performed the
experiments and wrote the paper. JKD and SES conducted clinical research
and contributed patient samples and provided demographic data. CAK
provided reagents for XMRV and advice on XMRV. RGM and FWM provided
control samples. JIC designed the experiments and wrote the paper.
Competing interests
The authors declare that they have no competing interests.
Received: 29 August 2011 Accepted: 24 September 2011
Published: 24 September 2011
References
1. Lombardi V, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS, Peterson DL,
Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B, Dean M, Silverman RH,
Mikovits JA: Detection of an infectious retrovirus, XMRV, in blood cells of
patients with chronic fatigue syndrome. Science 2009, 326:585-589.
2. Lo S-C, Pripuzova N, Li B, Komaroff AL, Hung GC, Wang R, Alter HA:
Detection of MLV-related virus gene sequences in blood of patients
with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad
Sci USA 2010, 107:15874-15879.
3. Groom HC, Boucherit VC, Makinson K, Randal E, Baptista S, Hagan S,
Gow JW, Mattes FM, Breuer J, Kerr JR, Stoye JP, Bishop KN: Absence of
xenotropic murine leukaemia virus-related virus in UK patients with
chronic fatigue syndrome. Retrovirology 2010, 7:10.
4. Erlwein O, Kaye S, McClure MO, Weber J, Wills G, Collier D, Wessely S,
Cleare A: Failure to detect the novel retrovirus XMRV in chronic fatigue
syndrome. PLoS One 2010, 5:e8519.
5. van Kuppeveld FJ, de Jong AS, Lanke KH, Verhaegh GW, Melchers WJ,
Swanink CM, Bleijenberg G, Netea MG, Galama JM, van der Meer JW:
Prevalence of xenotropic murine leukaemia virus-related virus in
patients with chronic fatigue syndrome in the Netherlands: retrospective
analysis of samples from an established cohort. BMJ 2010, 340:c1018.
6. Hong P, Li J, Li Y: Failure to detect xenotropic murine leukaemia virus-
related virus in Chinese patients with chronic fatigue syndrome. Virol J
2010, 7:224.
7. Switzer WM, Jia H, Hohn O, Zheng H, Tang S, Shankar A, Bannert N,
Simmons G, Hendry RM, Falkenberg VR, Reeves WC, Heneine W: Absence
of evidence of xenotropic murine leukemia virus-related virus infection
in persons with chronic fatigue syndrome and healthy controls in the
United States. Retrovirology 2010, 7:57.
8. Henrich TJ, Li JZ, Felsenstein D, Kotton CN, Plenge RM, Pereyra F, Marty FM,
Lin NH, Grazioso P, Crocheire DM, Eggers D, Kuritzkes DR, Tsibris AM:
Xenotropic murine leukemia virus-related virus prevalence in patients
with chronic fatigue syndrome or chronic immunomodulatory
conditions. J Infect Dis 2010, 202:1478-1481.
9. Knox K, Carrigan D, Simmons G, Teque F, Zhou Y, Hackett J Jr, Luk KC,
Schochetman G, Knox A, Kogelnik AM, Levy JA: No evidence of murine-
like gammaretroviruses in CFS patients previously identified as XMRV-
infected. Science 2011, 333:94-97.
10. Shin CH, Bateman L, Schlaberg R, Bunker AM, Leonard CJ, et al: Absence of
XMRV retrovirus and other murine leukemia virus-related retroviruses in
patients with chronic fatigue syndrome. J Virol 2011, 85:7195-7202.
11. Oakes B, Tai AK, Cingoz O, Henefield MH, Levine S, Coffin JM, Huber BT:
Contamination of human DNA samples with mouse DNA can lead to
false detection of XMRV-like sequences. Retrovirology 2010, 7:109.
12. Sato E, Furuta RA, Miyazawa T: An endogenous murine leukemia viral
genome contaminant in a commercial RT-PCR kit is amplified using
standard primers for XMRV. Retrovirology 2010, 7:110.
13. Hue S, Gray ER, Gall A, Katzourakis A, Tan CP, Houldcroft CJ, McLaren S,
Pillay D, Futreal A, Garson JA, Pybus OG, Kellam P, Towers GJ: Disease-
associated XMRV sequences are consistent with laboratory
contamination. Retrovirology 2010, 7:111.
14. Smith RA: Contamination of clinical specimens with MLV-encoding
nucleic acids: implications for XMRV and other candidate human
retroviruses. Retrovirology 2010, 7:112.
15. Paprotka T, Delviks-Frankenberry KA, Cigoz O, Kung HJ, Tepper CG, Hu WS,
Fivash MJ Jr, Coffin JM, Pathak V: Recombinant origin of the retrovirus
XMRV. Science 2010, 333:97-101.
16. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A: The
chronic fatigue syndrome-a comprehensive approach to its definition
and study. Ann Intern Med 1994, 121:953-959.
17. Mikovits JA, Ruscetti FW: Response to comments on Detection of an
infectious retrovirus XMRV in blood cells of patients with chronic fatigue
syndrome. Science 2010, 328:825.
18. Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR: XMRV is present in
malignant prostatic epithelium and is associated with prostate cancer,
Ali et al. Virology Journal 2011, 8:450
http://www.virologyj.com/content/8/1/450
Page 7 of 8
especially high-grade tumors. Proc Natl Acad Sci USA 2010,
106:16351-16356.
19. Switzer WM, Jia H, Zheng H, Tang S, Heneine W: No association of
xenotropic murine leukemia virus-related viruses in prostate cancer.
PLoS One 2011, 6:e19065.
20. Sakuma T, Hue S, Squillace KA, Tonne JM, Blackburn PR, Ohmine S,
Thatava T, Towers GJ, Ikeda Y: No evidence of XMRV in prostate cancer
cohorts in the Midwestern United States. Retrovirology 2011, 8:23.
21. Evans LH, Morrison RP, Malik FG, Portis J, Britt WJ: A Neutralizable epitope
common to envelope glycoproteins of ecotropic, polytropic, xenotropic,
and amphotropic murine leukemia viruses. J Virol 1990, 64:6176-6183.
22. Tuke PW, Tettmar KI, Tamuri A, Tedder RS: PCR master mixes harbor
murine DNA sequences. Caveat Emptor! PLoS One 2011, 6:e19953.
23. Furuta RA, Miyazawa T, Sugiyama T, Kuratsune H, Ikeda Y, Sato E, Misawa N,
Nakatomi Y, Sakuma R, Yasui K, Yamaguti K, Hirayama F: No association of
xenotropic murine leukemia virus with prostate cancer or chronic
fatigue syndrome in Japan. Retrovirology 2011, 8:20.
24. Satterfield BC, Garcia RA, Jia H, Tang S, Zheng H, Switzer WM: Serologic
and PCR testing of persons with chronic fatigue syndrome in the United
States shows no association with xenotropic or polytropic murine
leukemia virus-related viruses. Retrovirology 2011, 8:12.
25. Erlwein O, Robinson MJ, Kaye S, Wills G, Izui S, Wessley S, Weber J, Cleare J,
Collier D, McClure MO: Investigation into the presence of and serological
response to XMRV in CFS patients. PLoS One 2011, 6:e17592.
26. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K,
Magi-Galluzzi C, Tubbs RR, Ganem D, Silverman RH, DeRisi JL: Identification
of a novel gammaretrovius in prostate tumors of patients homozygous
for R462Q RNASEL variant. PLoS Pathog 2006, 2:e25.
27. Cloyd MW, Thompson MM, Hartley JW: Host range of mink cell focus-
inducing viruses. Virology 1985, 140:239-248.
doi:10.1186/1743-422X-8-450
Cite this article as: Ali et al.: Xenotropic murine leukemia virus-related
virus is not associated with chronic fatigue syndrome in patients from
different areas of the us in the 1990s. Virology Journal 2011 8:450.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ali et al. Virology Journal 2011, 8:450
http://www.virologyj.com/content/8/1/450
Page 8 of 8
